We evaluated the efficacy of these peptides and a previously described 13AA peptide derived from Borrelia flagellin, FlaB(211–223), as antigen targets for the detection of IgM and IgG in a large panel of sera from patients with early (EM+) or late (LA+) Lyme disease in an ELISA format (Table 1). This evidence concerns the gene CD40LG and Lyme disease.